Jiangsu Hengrui Pharmaceuticals Co.,Ltd (HKG:1276)

Market Cap	437.51B +51.2%
Revenue (ttm)	33.86B +19.2%
Net Income	8.16B +37.1%
EPS	1.27 +34.9%
Shares Out	n/a
PE Ratio	53.60
Forward PE	39.39
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,473,692
Average Volume	2,787,911
Open	70.65
Previous Close	70.60
Day's Range	69.75 - 71.45
52-Week Range	52.50 - 95.20
Beta	n/a
RSI	46.87
Earnings Date	Mar 26, 2026

About HKG:1276

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. It develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Employees: 20,238
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1276

Financial Performance

In 2024, HKG:1276's revenue was 27.98 billion, an increase of 22.63% compared to the previous year's 22.82 billion. Earnings were 6.34 billion, an increase of 47.28%.

Financial numbers in CNY